Biomarkers of Cellular Senescence and Aging: Current State‐of‐the‐Art, Challenges and Future Perspectives

Abstract

Population aging has increased the global prevalence of aging‐related diseases, including cancer, sarcopenia, neurological disease, arthritis, and heart disease. Understanding aging, a fundamental biological process, has led to breakthroughs in several fields. Cellular senescence, evinced by flattened cell bodies, vacuole formation, and cytoplasmic granules, ubiquitously plays crucial roles in tissue remodeling, embryogenesis, and wound repair as well as in cancer therapy and aging. The lack of universal biomarkers for detecting and quantifying senescent cells, in vitro and in vivo, constitutes a major limitation. The applications and limitations of major senescence biomarkers, including senescence‐associated β‐galactosidase staining, telomere shortening, cell‐cycle arrest, DNA methylation, and senescence‐associated secreted phenotypes are discussed. Furthermore, explore senotherapeutic approaches for aging‐associated diseases and cancer. In addition to the conventional biomarkers, this review highlighted the in vitro, in vivo, and disease models used for aging studies. Further, technologies from the current decade including multi‐omics and computational methods used in the fields of senescence and aging are also discussed in this review. Understanding aging‐associated biological processes by using cellular senescence biomarkers can enable therapeutic innovation and interventions to improve the quality of life of older adults.